Should expectant management serve as the primary treatment option in prostate cancer?
July 28th 2009Prostate cancer experts agree on one issue: No single treatment can be considered universal for men diagnosed with prostate cancer. There are myriad choices and considerations to be reviewed with every diagnosis. In addition, there are conflicting data about when, or if, men require screening for prostate cancer as well as when to start therapy for confirmed disease.
Folate polymorphisms underlie neuropsychological impairment in ALL survivors
November 1st 2008NIAGARA-ON-THE-LAKE, Canada- Previous studies have shown that 20% to 40% of survivors of childhood acute lymphoblastic leukemia will have some form of neuropsychological impairment. “However, we do not fully understand why some children are so strongly affected by therapy, and would like to develop a model to determine which children are most at risk for these negative late effects,” said Kala Y. Kamdar, MD, of the department of pediatric hematology/oncology, Baylor College of Medicine, Houston.
Growth hormone deficiency spurs late effects of childhood cancer
September 1st 2008NIAGARA-ON-THE-LAKE, Canada-Long-term survivors of childhood cancer are at increased risk of several late effects, including premature cardiovascular disease and insulin resistance as young adults. New research suggests that one cause of these conditions may be growth hormone deficiency (GHD) caused by cancer therapy.